| POS0340 EFFECTS OF CAR-T CELL TREATMENT ON B CELL IMMUNITY IN SYSTEMIC AUTOIMMUNE DISEASES L Bucci, T Rothe, F Müller, J Taubmann, M Hagen, C Bergmann, C Tur, ... Annals of the Rheumatic Diseases 83 (Suppl 1), 265-266, 2024 | | 2024 |
| POS0464 SERUM PROTEOMIC ANALYSIS IDENTIFIES MARKERS ASSOCIATED WITH ANTI-CD19 CAR T THERAPEUTIC RESPONSE IN AUTOIMMUNE DISEASES J Chou, R Grieshaber-Bouyer, D Bohr, C Bergmann, J Taubmann, ... Annals of the Rheumatic Diseases 83 (Suppl 1), 1131-1132, 2024 | | 2024 |
| POS0030 SAFETY AND PRELIMINARY EFFICACY OF CD19 CAR-T CELL TREATMENT IN RHEUMATIC DISEASE-DATA FROM THE FIRST PART OF THE PHASE I/II CASTLE BASKET STUDY G Schett, D Bohr, F Mueller, M Hagen, C Bergmann, C Tur, S Völkl, ... Annals of the Rheumatic Diseases 83 (Suppl 1), 327-327, 2024 | | 2024 |
| OP0027 LONG-TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN SEVERE AND TREATMENT REFRACTORY AUTOIMMUNE DISEASE J Taubmann, F Müller, F Fagni, C Bergmann, C Tur, L Bucci, S Völkl, ... Annals of the Rheumatic Diseases 83 (Suppl 1), 137-137, 2024 | | 2024 |
| OP0320 EFFICACY OF CD19-TARGETING CAR T CELL TREATMENT IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS (dSSc)–AN OPEN LABEL, SINGLE-CENTER PILOT STUDY J Auth, F Müller, J Taubmann, S Völkl, SC Fakhouri, L Bucci, M Aigner, ... Annals of the Rheumatic Diseases 83 (Suppl 1), 204-205, 2024 | | 2024 |
| Increased PD-1 Expression on Circulating T Cells Correlates with Inferior Outcome after Autologous Stem Cell Transplantation S Richter, M Böttcher, A Stoll, V Zeremski, S Völkl, A Mackensen, AB Ekici, ... Transplantation and Cellular Therapy 30 (6), 628. e1-628. e9, 2024 | | 2024 |
| The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany M Krebs, F Haller, S Spörl, E Gerhard-Hartmann, K Utpatel, K Maurus, ... European Journal of Cancer, 114144, 2024 | | 2024 |
| Liver-FDG-uptake and CAR T-cell kinetics augment early PET/CT prognostic value for CD19-targeted CAR T-cell therapy in diffuse large B cell lymphoma M Beck, V Blumenberg, V Bücklein, R Bundschuh, D Harrer, K Hirschbühl, ... | | 2024 |
| Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation J Winkler, H Tittlbach, A Schneider, I Vasova, J Strobel, S Herold, S Maas, ... Blood Advances 8 (10), 2373-2383, 2024 | 1 | 2024 |
| CAR T-cell therapy in rheumatology-What we know so far? M Hagen, A Wirsching, D Bohr, J Taubmann, F Müller, A Mackensen, ... Zeitschrift fur Rheumatologie, 2024 | | 2024 |
| CAR-T-Zell-Therapie in der Rheumatologie–Was wissen wir bisher? M Hagen, A Wirsching, D Bohr, J Taubmann, F Müller, A Mackensen, ... Zeitschrift für Rheumatologie, 1-7, 2024 | | 2024 |
| Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome JM Vinnakota, F Biavasco, M Schwabenland, C Chhatbar, RC Adams, ... Nature Cancer, 1-23, 2024 | | 2024 |
| Selective CAR-T cell mediated B cell depletion suppresses interferon signature in SLE A Wilhelm, D Chambers, F Müller, A Bozec, R Grieshaber-Bouyer, ... JCI insight, 2024 | 1 | 2024 |
| CAR T-Cell Therapy in Autoimmune Disease. Reply F Müller, A Mackensen, G Schett The New England journal of medicine 390 (17), 1631-1632, 2024 | | 2024 |
| Detection of signature double-negative T cells is a predictive marker to identify autoimmune lymphoproliferative syndrome associated with FAS loss of function N Eisenhauer, M Miano, N Naumann-Bartsch, J Leyh, G Dell'Orso, ... American journal of hematology 99 (5), 997-1000, 2024 | | 2024 |
| CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis T Krickau, N Naumann-Bartsch, M Aigner, S Kharboutli, S Kretschmann, ... The Lancet 403 (10437), 1627-1630, 2024 | 2 | 2024 |
| Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers L Fischer-Riepe, S Kailayangiri, K Zimmermann, R Pfeifer, M Aigner, ... Clinical Cancer Research, OF1-OF14, 2024 | 1 | 2024 |
| CD19 chimeric antigen receptor t cell treatment: unraveling the role of B cells in systemic lupus erythematosus J Taubmann, F Müller, M Yalcin Mutlu, S Völkl, M Aigner, A Bozec, ... Arthritis & Rheumatology 76 (4), 497-504, 2024 | 7 | 2024 |
| Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production J Dingfelder, M Aigner, J Taubmann, I Minopoulou, S Park, CD Kaplan, ... Transplantation and Cellular Therapy, 2024 | 1 | 2024 |
| 10.03 Long lasting alterations of the immunophenotype and cytokine signature of DLBCL survivors results in persisting immune dysfunction G Benintende, R Pelzl, K Wendland, F Gsottberger, S Petkovic, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 1), 2024 | | 2024 |
